Pharmacogenomics (PGx) is an exciting and powerful emerging field that promises to improve health care outcomes. PGx helps provide meaningful data that can help prevent adverse drug reactions and lower medical costs. When you partner with us, you gain access to a wide range of PGx genotyping solutions and the vast expertise we’ve acquired from a decade of driving advancements in PGx.
PGx research is part of the ongoing effort to tailor results to the individual by taking into account their genome, lifestyle, and other attributes. Like blood typing research before it, PGx research aims to avoid mismatches between individual cases and their respective approaches.
The future of health care includes factoring genetic test results into decisions.
Not sure where to begin? We can help you identify your testing requirements and make it easy for you to pick the right technology based on whether you need genotyping, copy number variation (CNV), and/or human leukocyte antigen (HLA) analysis.
Have content questions? We have carefully curated fixed content or flexible custom options, which will also guide your technology selection. We’re also here to help establish your workflow so that whether you’re testing for one target or 4,000, your lab is set up for success from the beginning. Rest assured that we continue to invest in developing innovative technologies that draw from our global network of specialists to make PGx accessible and affordable.
A flexible, scalable, and qualified solution for routine testing and more. Real-time PCR is optimal for routine testing and preemptive analysis using actionable genetic markers.
With the maximum amount of data available from samples, the Applied Biosystems PharmacoScan and PharmacoFocus microarray solutions are best positioned for research and development and preemptive analysis of all known markers.
|Real-time PCR||Next-generation sequencing||Microarray|
TaqMan SNP Genotyping Assays including OpenArray format
Ion AmpliSeq technology
PharmacoScan and PharmacoFocus Solutions
Genotyping, CNV, HLA
Number of targets
Up to 120 targets
>130 targets in 40 genes
PharmacoScan: ~4,500 targets in ~1,000 genes
Time to result
*Application supported via separate workflow
Top PGx thought leaders gathered to discuss the future of PGx testing and personalized medicine.
Dr. Jeffrey Shaman, Chief Science Officer at Coriell Life Sciences shares how PGx can enhance current wellness and medication risk management programs.
Read about Thermo Fisher Scientific's pharmacogenomics partnership with UPMC/University of Pittsburgh.
Real-time PCR solution for pharmacogenomics
For Research Use Only. Not for use in diagnostic procedures.